Mounjaro alternatives at a glance
Mounjaro and Zepbound are one drug, tirzepatide, sold by Eli Lilly under two labels. Mounjaro is approved for type 2 diabetes in adults and in children 10 and older, while Zepbound is approved for long-term weight management in adults with obesity, or with overweight and a weight-related condition. Drugs@FDA lists no approved generic of either one.
Mounjaro alternatives come in three kinds: tirzepatide in another form, a different GLP-1 drug, or a pill. Seven are below, and every one needs a prescription. Harbor's compounded tirzepatide and semaglutide, which are not FDA approved, are two of them: one weekly injection at home, medication, clinician care and check-ins in one flat price, and a licensed clinician who decides whether treatment fits.
| Option | Active drug | FDA status for weight | How it is taken |
|---|---|---|---|
| Mounjaro (reference) | Tirzepatide | Not labeled for weight (type 2 diabetes) | Injection, once a week |
| Zepbound pen (reference) | Tirzepatide | Approved, adults | Injection, once a week |
| Compounded tirzepatide | Tirzepatide | Not FDA approved | Injection, once a week |
| Zepbound vials | Tirzepatide | Approved, adults | Vial and syringe, once a week |
| Wegovy | Semaglutide | Approved, ages 12 and up | Injection, once a week |
| Compounded semaglutide | Semaglutide | Not FDA approved | Injection, once a week |
| Foundayo | Orforglipron | Approved, adults | Tablet once a day, with or without food |
| The Wegovy pill | Semaglutide | Approved, adults | Tablet each morning, empty stomach |
| Saxenda | Liraglutide | Approved, ages 12 and up | Injection, once a day |
Approval status and schedules from each current FDA label on DailyMed, read November 19, 2026. Compounded drugs are not FDA approved and carry no FDA label.
Mounjaro alternatives for weight loss
These Mounjaro alternatives for weight loss start with compounded tirzepatide, which is not FDA approved, and Zepbound vials, which keep brand tirzepatide in a different format. Next come Wegovy and compounded semaglutide, the second of which is also not FDA approved, then two daily pills, Foundayo and the Wegovy pill, and Saxenda. The list doubles as Zepbound alternatives, since Zepbound is the weight label of the same drug.
Trial figures in the brand entries come from separate trials of brand drugs, each with its own length and population, so read them as context and not as a ranking. None of those label trials tested a compounded drug. For the drug being replaced, see MedlinePlus tirzepatide injection facts.
Compounded tirzepatide
Weekly GIP and GLP-1 injection, not FDA approved
Compounded tirzepatide keeps the active ingredient of Mounjaro and Zepbound on the same once-weekly schedule, at a cash price that does not depend on insurance. It is a compounded drug, not FDA approved and not the same product as either brand, and the SURMOUNT and SURPASS trials tested the brand drugs only.
Where it wins
What it costs you
Staying on tirzepatide at one flat monthly price
Zepbound vials
Brand tirzepatide in a vial, FDA approved
Zepbound vials hold the same brand tirzepatide as the Zepbound pen, drawn into a syringe once a week. Zepbound has been FDA approved since November 8, 2023, for long-term weight management in adults with obesity, or with overweight and at least one weight-related condition.
Where it wins
What it costs you
Brand tirzepatide without the pen
Wegovy
Semaglutide injection, FDA approved 2021
Wegovy is brand semaglutide, a GLP-1 receptor agonist injected once a week and FDA approved on June 4, 2021. Its label covers long-term weight management in adults and children 12 and older with obesity, and adults with overweight plus a condition tied to weight.
Where it wins
What it costs you
A weekly brand GLP-1 when your plan covers it
Compounded semaglutide
Weekly GLP-1 injection, not FDA approved
Compounded semaglutide suits a reader whose clinician recommends a GLP-1-only option, the drug in Wegovy, in a weekly injection at a cash price that does not depend on insurance. It is a compounded drug, not FDA approved and not the same product as Wegovy.
Where it wins
What it costs you
A weekly GLP-1-only option at one flat price
Foundayo
Orforglipron tablet, FDA approved 2026
Foundayo (orforglipron) is a once-daily GLP-1 pill that FDA approved on April 1, 2026, for long-term weight management in adults with obesity, or with overweight and at least one weight-related condition.
Where it wins
What it costs you
A daily pill with no food timing
The Wegovy pill
Semaglutide tablet, FDA approved 2025
The Wegovy pill is semaglutide as a once-daily tablet, FDA approved on December 22, 2025. Its label covers long-term weight management in adults, and lowering the risk of major cardiovascular events in adults with heart disease and obesity or overweight.
Where it wins
What it costs you
Brand semaglutide in tablet form
Saxenda
Liraglutide injection, FDA approved 2014
Saxenda is liraglutide 3 mg, a GLP-1 receptor agonist injected once a day. Approved on December 23, 2014, it is the oldest approval on this list, and a generic liraglutide injection with the same weight-management indication is now listed on DailyMed.
Where it wins
What it costs you
When a generic GLP-1 matters most
How to choose a Zepbound alternative
The right Zepbound alternative depends on why the brand pen is not working out for you, because cost, coverage, needles and the drug itself each point somewhere else.
| Your reason | Options to raise with a clinician |
|---|---|
| Cost, or no coverage | Compounded tirzepatide in a cash-pay program (not FDA approved), or the brand your plan does cover |
| You want to stay on tirzepatide | Compounded tirzepatide (not FDA approved) or Zepbound vials |
| You want a different drug | Wegovy, or compounded semaglutide (not FDA approved) |
| You want a pill | Foundayo or the Wegovy pill |
| You want an FDA-approved generic | Generic liraglutide, the drug in Saxenda |
| You take Mounjaro for type 2 diabetes | The clinician who manages your diabetes, before any change |
A starting point for the conversation, not a prescription. Harbor offers the two compounded injections, and no pill, brand drug or liraglutide.
If the problem is paying for Zepbound without insurance, coverage is uneven to begin with. NIDDK notes that some, but not all, insurance plans cover medications that treat overweight and obesity. A cash-pay program removes the coverage question, though never the prescription.
Compounded drugs are not FDA approved, and FDA advises getting a prescription and filling it at a state-licensed pharmacy. Whether a compounded drug fits you is the prescribing clinician's call. Why the two routes are priced so differently is explained in tirzepatide brand vs compounded price.
What a clinician checks first
Every drug on this list is ruled out by a personal or family history of medullary thyroid carcinoma or MEN 2. The Zepbound label also advises against using it with any other tirzepatide product or GLP-1 drug, so a move to another option is a switch and never an add-on. The compounded programs are for adults 18 and older and are not available during pregnancy, breastfeeding or while planning a pregnancy. For your own history, message your clinician.
Compounded tirzepatide shots with Harbor
For a reader leaving Mounjaro or Zepbound over cost or coverage, the closest routine is another weekly tirzepatide shot. Harbor compounded tirzepatide, which is not FDA approved, is a once-weekly injection you give yourself at home, in a program that puts medication, clinician care and check-ins in one price. No insurance is required, and HSA and FSA cards are accepted.
The compounded tirzepatide cost in this program starts at $119 a month and stays flat as your dose goes up. Kendra Freeman described the pricing on Trustpilot in August 2026: "Needing to up your dose great no problem costs stay the same."
It is not Mounjaro or Zepbound, and it is not a generic of either. A board-certified physician licensed in your state reviews your intake and decides whether treatment is appropriate before anything ships. If a clinician does not approve treatment, the payment is refunded in full.
Switching from a brand pen starts with three details in your intake: your current medication, your dose and the date of your last injection. In most cases you can continue at your current dose or request an increase rather than restarting titration, and your provider makes the final call. A member who switched, Hope Osborne, wrote on Trustpilot in October 2026 that support "made the whole change feel much less complicated."
Each shipment of the compounded tirzepatide, which is not FDA approved, holds a multi-dose vial, U-100 insulin syringes, alcohol prep pads and a sharps container. The program is also designed to end: when you reach your goal, it moves to a structured, clinician-guided taper and registered-dietitian aftercare. The online quiz takes about 90 seconds, and there is no charge to find out.
Medical disclaimer
This article is for general education and is not medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a licensed clinician. Talk with a qualified clinician about your individual situation.
Compounded medications
Harbor is a technology platform. Medical evaluations are conducted by independent, licensed healthcare providers who determine whether treatment is appropriate. Compounded medications are not FDA approved and are not reviewed by the FDA for safety or effectiveness.
Frequently asked questions
There is no generic tirzepatide yet: as of November 2026, Drugs@FDA lists only Mounjaro and Zepbound. The lower-cost routes to ask about are your plan's coverage, since some plans cover weight medication, and a cash-pay Mounjaro alternative such as a compounded tirzepatide program, which is not FDA approved, from $119 a month with no insurance required. Which costs you less depends on your plan and your dose, so compare what each monthly price includes.
Harbor's compounded tirzepatide, which is not FDA approved, starts at $119 a month, and that one price covers the medication, clinician care and check-ins. The price stays flat as your dose goes up, there are no membership fees, and HSA and FSA cards are accepted. Prepaid plans billed every 3, 6 or 12 months are discounted against monthly billing.
It depends on the option. Semaglutide, the drug in Wegovy, has been tested against tirzepatide directly: in SURMOUNT-5, a 72-week trial of 751 adults, mean weight loss was 20.2% on tirzepatide and 13.7% on semaglutide. Foundayo, the Wegovy pill and Saxenda were each tested against placebo, not against Zepbound. Compounded tirzepatide, which is not FDA approved, was not part of any of these trials, so whether it fits you is a licensed clinician's decision, made after reviewing your history.
Sources
- Mounjaro (tirzepatide) label, revised August 2026, DailyMed.
- Mounjaro NDA 215866 approval history, Drugs@FDA.
- Zepbound (tirzepatide) label, revised August 2026, DailyMed.
- Zepbound NDA 217806 approval history, Drugs@FDA.
- SURMOUNT-5, tirzepatide compared with semaglutide (NCT05822830), ClinicalTrials.gov.
- Wegovy (semaglutide) injection and tablets label, DailyMed.
- Wegovy injection NDA 215256 approval history, Drugs@FDA.
- Wegovy tablets NDA 218316 approval history, Drugs@FDA.
- Foundayo (orforglipron) tablets label, DailyMed.
- FDA approves Foundayo (orforglipron), April 1, 2026.
- Saxenda (liraglutide) label, DailyMed.
- Saxenda NDA 206321 approval history, Drugs@FDA.
- Liraglutide injection (generic, weight management) label, DailyMed.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss.
- Prescription medications to treat overweight and obesity, NIDDK.
- Tirzepatide injection, MedlinePlus drug information.






